In preclinical diet-induced obese MASH mouse and hamster models, the triple GIP/GLP-1/glucagon receptor agonist retatrutide was reported to reduce body weight, hepatic steatosis and liver triglycerides, and HOMA-IR insulin resistance, with changes in food intake. Findings are limited to these animal models and do not establish human efficacy.
Retatrutide
A peptide investigated for its action at three hormone receptors involved in metabolism. Explore the specific clinical studies below.
The short version
A peptide investigated for its action at three hormone receptors involved in metabolism. Explore the specific clinical studies below.
What does the research tell us?
A result in a cell or an animal does not establish the same result in people. Read the study design, the measurements, and the limitations before drawing a conclusion.
What remains uncertain?
The research question, the formulation, and the population all matter. This page is a starting point for understanding the literature, not a complete assessment of benefits or risks.
Identity & technical details
For readers who want the reference details.
- Name
- Retatrutide
- Also known as
- LY3437943, GGG tri-agonist
- Topic
- Metabolism
- CAS
- 2381089-83-2
Explore the sources
Open a source to read its methods and limitations. Published titles are kept in their original language.
In this rodent study, the GLP-1R:GIPR:GCGR triagonist retatrutide was reported to normalize body weight in diet-induced obese GLP-1R-knockout mice, indicating retatrutide-driven weight reduction can occur without functional GLP-1 receptor signaling; a GIPR:GCGR co-agonist lacking GLP-1 activity lowered excess body weight comparably.
In a high-fat-diet mouse model, multi-omic profiling reported that the GIP/GLP-1/glucagon triple agonist retatrutide was associated with reduced adipose-tissue fibrosis — downregulated inflammatory/fibrotic pathways and upregulated reparative signaling — alongside metabolic reprogramming toward fatty-acid oxidation and improved mitochondrial function.
This review characterizes retatrutide (LY3437943) in the literature as a single-molecule triple receptor agonist acting on the GLP-1, GIP, and glucagon receptors, situating it within the broader development of multi-hormonal peptide pharmacology described for obesity and cardiometabolic comorbidities.
This guide explains research. It does not recommend a treatment, product, or dose.
A laboratory arithmetic tool. It does not determine a dose for a person.
Peptidoteca is part of the same business portfolio as ReadyPep. Commercial relationships should be considered when reading our content.
ReadyPep · Research supplies ↗